MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-17-2026
Boston Scientific Corporation Net Debt 2011-2026 | BSX
Net Debt can be roughly defined as financial liabilities that an entity classifies in the financing section together with the resources available to service those financial liabilities[1]
Net debt is the obligations that remain after deducting all assets and other liabilities from a company or individual. It represents the sum of debts that an organization or person must repay to their creditors or other parties.
Net debt can include various types of obligations such as loans, borrowings, lease liabilities, or credit card payments. It is important to note that net debt does not include current expenses or obligations such as payroll expenses or current bills.
Assessing net debt is an important financial indicator for evaluating the financial position of a company or individual. If net debt significantly exceeds assets, it may indicate financial difficulties and insolvency. In such cases, the company or individual may face difficulties in meeting their obligations and managing their finances.
Net debt can also be used to compare the financial stability of different companies. The lower the net debt relative to assets, the more stable and financially sound they are considered.
Overall, understanding net debt helps evaluate the financial soundness and ability of a company to meet their obligations. It is an important indicator that assists in making decisions about lending, investments, and financial management.
Annual Net Debt Boston Scientific Corporation
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 9.26 B | 8.64 B | 7.78 B | 8.05 B | 6.95 B | 7.38 B | 9.78 B | 6.88 B | 5.39 B | 5.29 B | 5.36 B | 3.68 B | 4.02 B | 4.05 B | 3.99 B |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 9.78 B | 3.68 B | 6.43 B |
References
- Pizzo, M., Moscariello, N., & Vinciguerra, R. (2015). Market Incentives and Regulators' Activity Shaping Financial Information: An Analysis of the Net Debt Disclosure in Italy. International Journal of Business and Management, 10(1), 1.
Net Debt of other stocks in the Medical devices industry
| Issuer | Net Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Aethlon Medical
AEMD
|
-4.85 M | $ 2.22 | - | $ 3.47 M |  USA |
 |
Acutus Medical
AFIB
|
14.2 M | - | -26.83 % | $ 2.62 M | USA |
 |
Allied Healthcare Products
AHPI
|
-3.31 M | - | 3.58 % | $ 2.21 M | USA |
 |
AdaptHealth Corp.
AHCO
|
1.64 B | $ 10.36 | -0.86 % | $ 1.4 B | USA |
 |
GenMark Diagnostics, Inc.
GNMK
|
38.7 M | - | - | $ 1.77 B | USA |
 |
Alphatec Holdings
ATEC
|
347 M | $ 12.95 | -0.77 % | $ 1.94 B | USA |
 |
Obalon Therapeutics, Inc.
OBLN
|
6.46 M | - | -5.86 % | $ 30.6 M | USA |
 |
Avinger
AVGR
|
-16.3 M | - | -20.74 % | $ 369 K | USA |
 |
Cognyte Software Ltd.
CGNT
|
-47.4 M | $ 8.36 | - | $ 600 M |  Israel |
 |
Aziyo Biologics
AZYO
|
-32.4 M | - | 1.37 % | $ 20.5 M | USA |
 |
Butterfly Network
BFLY
|
-65.9 M | $ 4.17 | -2.11 % | $ 883 M | USA |
 |
ClearPoint Neuro
CLPT
|
3.85 M | $ 10.09 | -9.59 % | $ 286 M | USA |
 |
BIOLASE
BIOL
|
6.1 M | - | -13.19 % | $ 166 K | USA |
 |
Conformis
CFMS
|
-26.2 M | - | - | $ 16.4 M | USA |
 |
Cytosorbents Corporation
CTSO
|
11.2 M | $ 0.68 | 0.71 % | $ 37 M | USA |
 |
Apollo Endosurgery
APEN
|
-22.5 M | - | - | $ 475 M | USA |
 |
EDAP TMS S.A.
EDAP
|
-22.8 M | $ 4.0 | -1.23 % | $ 149 M |  France |
 |
CONMED Corporation
CNMD
|
802 M | $ 36.89 | -0.78 % | $ 1.14 B | USA |
 |
InMode Ltd.
INMD
|
-34.8 M | $ 13.65 | - | $ 882 M | Israel |
 |
CryoLife, Inc.
CRY
|
230 M | - | -4.14 % | $ 702 M | USA |
 |
Establishment Labs Holdings
ESTA
|
174 M | $ 64.4 | -0.95 % | $ 1.91 B |  Costa-rica |
 |
Cutera
CUTR
|
-140 M | - | -10.19 % | $ 1.99 M | USA |
 |
Dynatronics Corporation
DYNT
|
1.8 M | - | 14.99 % | $ 929 K | USA |
 |
Axonics Modulation Technologies
AXNX
|
-230 M | - | - | $ 3.31 B | USA |
 |
Soliton, Inc.
SOLY
|
-31.6 M | - | -1.42 % | $ 435 M | USA |
 |
Hancock Jaffe Laboratories, Inc.
HJLI
|
-9.02 K | - | -1.98 % | $ 98.3 M | USA |
 |
Itamar Medical Ltd.
ITMR
|
-2.3 M | - | 0.03 % | $ 1.58 B | Israel |
 |
Misonix, Inc.
MSON
|
5.72 M | - | - | $ 462 M | USA |
 |
Neovasc
NVCN
|
-4.95 M | - | - | $ 111 M |  Canada |
 |
FONAR Corporation
FONR
|
-42.8 M | $ 18.43 | -0.11 % | $ 121 M | USA |
 |
Intersect ENT, Inc.
XENT
|
50.8 M | - | - | $ 955 M | USA |
 |
GBS
GBS
|
-4.38 M | - | -0.57 % | $ 7.12 M | USA |
 |
Abbott Laboratories
ABT
|
1.65 B | $ 109.42 | -1.2 % | $ 191 B | USA |
 |
Delcath Systems
DCTH
|
-42.5 M | $ 9.58 | -1.64 % | $ 343 M | USA |
 |
Bio-Rad Laboratories
BIO
|
754 M | $ 266.27 | -1.15 % | $ 7.51 B | USA |
 |
IRIDEX Corporation
IRIX
|
-4.29 M | $ 1.33 | - | $ 21.5 M | USA |
 |
OrthoPediatrics Corp.
KIDS
|
83.3 M | $ 17.02 | -1.07 % | $ 399 M | USA |
 |
Helius Medical Technologies
HSDT
|
-5.12 M | $ 2.11 | -2.88 % | $ 1.28 M | USA |
 |
AxoGen
AXGN
|
15.2 M | $ 32.52 | -0.7 % | $ 1.5 B | USA |
 |
Align Technology
ALGN
|
-925 M | $ 174.5 | -0.92 % | $ 13.1 B | USA |
 |
Integra LifeSciences Holdings Corporation
IART
|
529 M | $ 8.95 | -1.65 % | $ 689 M | USA |
 |
Bruker Corporation
BRKR
|
1.91 B | $ 33.37 | -1.1 % | $ 4.97 K | USA |
 |
BioSig Technologies
BSGM
|
252 K | - | 37.08 % | $ 85.7 M | USA |
 |
Apyx Medical Corporation
APYX
|
3.52 M | $ 3.8 | 1.6 % | $ 156 M | USA |
 |
Second Sight Medical Products
EYES
|
961 K | - | -0.97 % | $ 54.4 M | USA |
 |
Accuray Incorporated
ARAY
|
73.7 M | $ 0.38 | -1.84 % | $ 39.1 M | USA |
 |
IRadimed Corporation
IRMD
|
-52.1 M | $ 102.06 | -0.72 % | $ 1.3 B | USA |